Prolonged stabilization of progressive platinum-refractory ovarian cancer with paclitaxel: Brief report

European Journal of Gynaecological Oncology

Volumn 17, Issue 4, 1996, Pages 264-266

  Balat, O ^a   Kudelka, A P ^a   Tunca, J C ^b   Edwards, C L ^c   Verschraegen, C ^a   Kavanagh, J J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c Box 39 ^*

Author keywords

Ovarian cancer; Paclitaxel; Prolonged administration

Indexed keywords

CARBOPLATIN; ETOPOSIDE; FLUTAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LEUPRORELIN; PACLITAXEL; PLATINUM; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; FEMALE; GRANULOCYTOPENIA; HUMAN; OVARY CANCER; QUALITY OF LIFE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYSTADENOCARCINOMA, PAPILLARY; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; QUALITY OF LIFE; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 0029744501     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Boring C. C., Squires T. S., Tong T.: "Cancer statistics, 1994". CA Cancer J. Clin., 1994, 44, 7.
2. Kavanagh J. J., Kudelka A.: "Systemic therapy for gynecologic cancer". Curr. Opin. Oncol., 1993, 5, 891.
3. Ozols R. F., Young R. C.: "Chemotherapy of ovarian cancer". Semin. Oncol., 1991, 18, 222.
4. Pazdur R., Kudelka A. P., Kavanagh J. J., et al.: "The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere)". Cancer Treat. Rev., 1993, 19, 351.
5. Holmes F. A., Kudelka A. P., Kavanagh J. J., et al.: "Current status of clinical trials with paclitaxel and docetaxel". In: Georg G. I., Chen T. C., Ojima I., Vyas D. M. (eds.): American Chemical Society Symposium-in-print. Taxane Anticancer Agent: Basic Science and Current Status, 1995, 3, 31.
6. McGuire W. P., Rowinsky E. K., Rosenshein N. B., et al.: "Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms". Ann. Intern. Med., 1989, 11, 273.
7. Einzig A. I., Wiernik P. H., Sasloff J., et al.: "Phase II study and long term follow-up of patient treated with Taxol for advanced ovarian adenocarcinoma". J. Clin. Oncol., 1992, 10, 1748.
8. Thigpen T., Blessing J., Ball H., et al.: "Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study". J. Clin. Oncol., 1994, 12, 1748.
9. Kavanagh J. J., Kudelka A., Edwards C. L., et al.: "A randomized crossover trial of parenteral hydroxyurea vs high dose taxol in cisplatin/carboplatin resistant epithelial ovarian carcinoma". Proc. Am. Soc. Clin. Oncol., 1993, 12, 259.
10. Donehower R. C., Rowinsky E. K., Grochow L. B., et al.: "Phase I trial of taxol in patients with advanced cancer". Cancer Treat. Rep., 1987, 71, 1171.
11. Srosy G., Kohn E., Link C., et al.: "Taxol dose intensification in patients with recurrent ovarian cancer'". Proc. Am. Soc. Clin. Oncol., 1992, 11.